Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]-
6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine
CAS: 1800046-95-0
Molecular Formula: C23H25N9O
Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]- - Names and Identifiers
Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]- - Physico-chemical Properties
| Molecular Formula | C23H25N9O |
| Molar Mass | 443.5 |
| Density | 1.52±0.1 g/cm3(Predicted) |
| Solubility | DMSO : 15 mg/mL, ultrasound can increase solubility mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, try to use it now) Cell experiment: dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concent |
| pKa | 6.34±0.70(Predicted) |
| Storage Condition | -20℃ |
| Use | Lanraplenib (GS-9876) is a highly selective oral SYK inhibitor (IC50=9.5 nM) used to study inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets through glycoprotein VI (GPVI) receptors without prolonging bleeding time (BT) in monkeys or humans. |
| Target | SYK |
Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]- - Reference
| Reference Show more | 1. Blomgren P, Chandrasekhar J, Di Paolo JA, Fung W, Geng G, Ip C, Jones R, Kropf JE, Lansdon EB, Lee S, Lo JR, Mitchell SA, Murray B, Pohlmeyer C, Schmitt A, Suekawa-Pirrone K, Wise S, Xiong JM, Xu J, Yu H, Zhao Z, Currie KS. Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. ACS Med Chem Lett. 2020 Feb 12;11(4):506-513. doi: 10.1021/acsmedchemlett.9b00621. PMID: 32292557; PMCID: PMC7153012.2. Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, Bubb M, Lim S, Hajian H, Gurtovaya O, Patel U, Tumlin J. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020 Dec;6(3):e001490. doi: 10.1136/rmdopen-2020-001490. PMID: 33380521; PMCID: PMC7780527. |
Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]- - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.256 ml | 11.281 ml | 22.562 ml |
| 5 mM | 0.451 ml | 2.256 ml | 4.512 ml |
| 10 mM | 0.226 ml | 1.128 ml | 2.256 ml |
| 5 mM | 0.045 ml | 0.226 ml | 0.451 ml |
Last Update：2024-01-02 23:10:35
![Imidazo[1,2-a]pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]-](http://res.chembk.com/assets/images/structure/1002455.gif)
Supplier List
Spot supply
Product Name: 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine Visit Supplier Webpage Request for quotationCAS: 1800046-95-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine Visit Supplier Webpage Request for quotationCAS: 1800046-95-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History